

Full Length Research Paper

## Molecular characterization of adenovirus causing acute respiratory disease in Malaysia from 2003 to 2011

Mohd Apandi Y.\*, Zarina M. Z., Khairul Azuan O., Nur Ismawati A. R. and Zainah S.

Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia.

Accepted 13 August, 2013

**Human Adenoviruses (HAdVs) are human pathogens that normally are associated with acute respiratory disease (ARD). Here, in this study, we characterized human adenovirus isolated from respiratory specimens collected from 2003 to 2011. Positive adenovirus were confirmed by cell culture and indirect immunofluorescence (IF) techniques. The isolates and positive clinical samples were subjected to adenovirus polymerase chain reaction, followed by DNA sequencing. BLAST searches and phylogenetic analysis revealed that only 2 species of HAdV, species C at 64% (47/73) and species B at 36% (26/73) were found circulating amongst ARD cases in Malaysia. Four types of HAdV species C were detected namely: HAdV-2 (66%), HAdV-1(17%), HAdV-5(13%) and HAdV-6(4%). For HAdV species B, only 2 types were detected with HAdV-3 being the highest at 58% and HAdV-7 at 42%. HAdV-7 was associated with severe infections.**

**Key words:** Human adenoviruses, acute respiratory disease, molecular characterization, gene sequences.

### INTRODUCTION

Human Adenoviruses (HAdVs) were first isolated from human adenoids and identified as respiratory pathogens in 1953 (Rowe et al., 1953; Hilleman et al., 1954) and now HAdVs have been recognized as aetiological agent for variety of diseases. It is a common infectious agent in children less than 5 years and responsible for 5 to 10% of all lower respiratory tract infections in infants and children (Choi et al., 2006). They are ubiquitous, non-enveloped, double stranded DNA in the family of *Adenoviridae*. Diseases in human such as pharyngitis, pneumonia, gastroenteritis, haemorrhagic cystitis and keratoconjunctivitis have been associated with HAdVs infections (Mandell et al., 2009). The severity of the disease also ranges from mild or inapparent clinical syndromes to severe life threatening disease in immunocompromised individuals (Mandell et al., 2009). Infections with HAdVs can occur sporadically or in epidemics; and the virus can be isolated and identified throughout the

year (Hong et al., 2001). HAdVs are also responsible for outbreaks in settings that have close living condition such as in military barracks (Dudding et al., 1972), hospital wards (Straube et al., 1983), chronic care facilities (Finn et al., 1988) and police academy (Apandi et al., 2012). Previously, HAdVs were classified by haemagglutination and serum neutralization (Seto et al., 2011). Since genomic data and bioinformatics became available, new HAdVs have been identified including several emerging and recombinant viruses (Walsh et al., 2011) and today there are 57 recognised serotypes in 7 species, HAdV-A to HAdV-G (Martin et al., 2007). The hexon protein with serotype specific encoded by seven hyper variable regions (Crawford and Schnurr, 1996) is the most important components for serotype identification of adenoviruses (Takeuchi et al., 1999).

Epidemiologic characteristics of the HAdV vary by type. All are transmitted by direct contact, faecal oral transmission

\*Corresponding author. E-mail: [apandi@imr.gov.my](mailto:apandi@imr.gov.my).

and occasionally waterborne transmission. Depending on the species, these viruses may infect respiratory, conjunctival, gastrointestinal and genitourinary sites and specific types have been linked to distinct clinical syndromes. Recently, HAdV have emerged as life-threatening opportunistic agents in severely immune-suppressed patients, such as stem cell recipients (Ganzenmueller et al., 2011). The outbreak of adenoviruses associated with respiratory disease has been reported worldwide (Schmitz et al., 1983; Zhu et al., 2009; Trei et al., 2010). The serotypes that most frequently associated with acute respiratory disease (ARD) were from species B and C. HAdV-3 and HAdV-7 in species B were reported as a common cause of severe pneumonia in neonates and young children (Carballal et al., 2002; Tsolia et al., 2004); whereas, HAdV-11 and HAdV-14 have been reported in febrile respiratory disease outbreaks in all ages (Kajon et al., 2010; Gu et al., 2012). In the species C, serotypes HAdV-1, HAdV-2, HAdV-5 and HAdV-6 were endemic in parts of the world (CDC, 2007) and cause febrile respiratory illnesses in children and young adults (Metzgar et al., 2005; Abd-Jamil et al., 2010). HAdV-4 was the only serotype in species C that involved in ARD (Rubin, 1993; Kandel et al., 2010).

The objectives of the study were to determine the type of HAdV circulating from 2003 to 2011 and the association of HAdV type with severe acute respiratory disease. Therefore, we characterized all HAdVs associated with respiratory illness from samples received by the Institute for Medical Research (IMR) from patients who sought treatment for respiratory infection in the government hospitals in Malaysia.

## MATERIALS AND METHODS

### Virus

From 2003 to 2011, IMR received samples from 10,972 patients who seek treatment at 140 government hospitals for respiratory illness such as acute respiratory distress, pneumonia, bronchiolitis and bronchopneumonia. All samples were screened for respiratory viruses including adenovirus by indirect immunofluorescence assay (IFA respiratory panel 1 Kit, Millipore, UK) and cell culture technique. In the IFA technique, samples were considered positive for adenovirus when fluorescence was present in the nucleus or cytoplasm of the cells; whereas in tissue culture solely based on the appearance of the cytopathic effect (CPE). Positive samples by cell culture were recultured in Vero cells and harvested when cells showed CPE.

### DNA extraction and PCR

Viral nucleic acid was extracted from the samples by using Roche high pure viral nucleic acid kit (Roche Applied Science, Mannheim, Germany). Briefly, 200 µl of sample was added to binding buffer supplemented with poly (A) and proteinase K in a microcentrifuge tube and incubated at 72°C for 10 min. Later, binding buffer was added and the mixture was transferred to high pure filter tube for centrifugation. Inhibitor removal buffer was used to remove PCR inhibitors and wash buffer for removal of residual impurities. Finally, elution buffer was added to elute viral nucleic acid in a clean micro-

centrifuge tube. Nested PCR was used to amplify the HAdV hexon gene. First PCR primer pair, forward primer HEXB-1 (5'-AAC ATG ACC AAR GAC TGG TT-3') and reverse primer HEXB-2 (5'-GCC GAG AAS GGY GTR CGC AGG TA -3') (IHCM, 2003) in a one tube reaction (20 µl) containing 10 µl DNA, 1 µl of 20 µM of each primer, 2.0 µl of 25 mM MgCl<sub>2</sub> with 10X PCR buffer, 0.6 µl of 10 mM dNTP, 0.5 µl of 5 U/µl Taq DNA polymerase and nuclease free water. Samples were subjected to 35 PCR cycles, denaturation at 95°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 30 s; and final extension at 72°C for 5 min. For the second PCR, forward primer HEXB-3 (5'-TTC AGA AAC TTC CAG CCY ATG AG-3') and reverse primer HEXB-4 (5'-TCC ATG GGA TCC ACC TCA AAR GTC AT-3') (IHCM, 2003) were used and 5 µl of first PCR product was used as a template and PCR was performed using the same conditions as the first PCR.

Expected PCR products (360 bp) were examined by gel electrophoresis and QIAquick gel extraction kits (QIAGEN Inc, Valencia, CA) was used to extract the DNA from the gel.

### Nucleotide sequencing and phylogenetic analysis

The partial hexon gene amplicons were sequenced on both strands by using primers HEXB-3 and HEXB-4. Sequencing was performed by using the Big Dye Cycle Sequencing kit version 3.0 and an ABI377 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). The SeqMan software module in the Lasergene suite of programs (DNASTAR, Madison, WI, USA) was used to format the nucleotide sequences. Alignment of the gene sequences was undertaken by using the MegAlign software module in the Lasergene suite of programs (DNASTAR, Madison, WI, USA). Phylogenetic tree was constructed by using the neighbour-joining method from the Software MEGA4 (Tamura et al., 2007). The duck adenovirus type 1 was used as an outgroup for phylogenetic analysis together with different species of adenovirus obtained from GenBank for the purpose of generating dendrograms. All sequences were submitted to GenBank with accession number JX182290-JX183062.

## RESULTS

More than 76% specimens found positive for adenoviruses were derived mainly from nasopharyngeal aspirate (NPA) from children less than 5 years of age diagnosed with ARD (Table 1). All 73 positive adenovirus samples, 30 positive by tissue culture and 43 IFA positive were subjected to adenovirus polymerase chain reaction (PCR), and followed by DNA sequencing. Type of samples received, year of isolation, diagnosis and types of adenovirus isolated are shown in Table 1. All positive samples were sequenced, and basic local alignment search tool (BLAST) sequencing analysis (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) showed that the sequences belonged to HAdV-1, HAdV-2, HAdV-3, HAdV-5, HAdV-6 and HAdV-7. Phylogenetic tree, constructed on the basis of partial hexon gene (348 bp) nucleotides of all adenoviruses isolated from 2003 to 2011 together with adenovirus isolates retrieved from GenBank is shown in Figure 1. In 2003, only 2 HAdV-7 were detected from ARD specimens and no adenoviruses were detected in 2004. The following year, in 2005, 2 HAdVs were detected and were identified as HAdV-1 and HAdV-2. HAdV detection rate started to increase in 2006, with 10 HAdV-2 and 1 HAdV-1. The number increased to

**Table 1.** Summary of patients' gender, age, sample type, clinical diagnosis, HAdV typing result and GenBank accession number.

ID	Accession No.	Sample type	Sex/age	Clinical diagnosis	Isolation year	Adenovirus type
RV0227/03	JX182990	TA (i)	M/1.3	Respiratory distress	2003	Ad7
RV0259/03	JX182991	NPA (i)	M/1.5	Pneumonia	2003	Ad7
RV0092/05	JX182992	NPA (i)	M/2.5	Pneumonia	2005	Ad1
RV0198/05	JX182993	Sputum (i)	M/6	Chronic lung Disease	2005	Ad2
RV0700/06	JX182994	NPA (i)	M/0.3	Bronchopneumonia	2006	Ad1
RV1007/06	JX183003	NPA (p)	M/0.3	Pneumonia	2006	Ad2
RV1009/06	JX182995	NPA (p)	M/0.3	Bronchopneumonia	2006	Ad2
RV1016/06	JX182996	NPA (p)	M/0.6	Bronchopneumonia	2006	Ad2
RV1027/06	JX182997	NPA (p)	F/1.0	Severe pneumonia	2006	Ad2
RV1067/06	JX183002	NPA (p)	F/2.4	Bronchopneumonia	2006	Ad2
RV1083/06	JX182998	NPA (p)	F/0.1	Bronchopneumonia	2006	Ad2
RV1093/06	JX183004	NPA (p)	M/0.3	Bronchiolitis	2006	Ad2
RV1095/06	JX182999	NPA (p)	F/1.1	Pneumonia	2006	Ad2
RV1111/06	JX183000	NPA (p)	M/0.3	Pneumonia	2006	Ad2
RV1115/06	JX183001	NPA (p)	M/0.1	Pneumonia	2006	Ad2
RV0004/07	JX183005	NPA (p)	M/1.0	Severe bronchopneumonia	2007	Ad3
RV0037/07	JX183006	NPA (p)	M/0.1	Pneumonia	2007	Ad2
RV0062/07	JX183007	NPA (p)	M/0.5	Pneumonia	2007	Ad2
RV0114/07	JX183014	TA (p)	M/7.0	Bronchopneumonia	2007	Ad2
RV0353/07	JX183015	NPA (p)	F/1.5	Pneumonia	2007	Ad5
RV0440/07	JX183019	NPA (p)	M/1.0	Pneumonia	2007	Ad1
RV0447/07	JX183008	NPA (p)	M/0.1	pneumonia	2007	Ad2
RV0533/07	JX183009	NPA (p)	M/0.8	pneumonia	2007	Ad3
RV0603/07	JX183017	NPA (p)	F/6.4	Pneumonia	2007	Ad2
RV0619/07	JX183013	NPA (p)	M/0.7	Bronchopneumonia	2007	Ad1
RV1031/07	JX183010	NPA (p)	M/0.8	Bronchopneumonia	2007	Ad1
RV1312/07	JX183018	NPA (p)	M/0.5	Bronchopneumonia	2007	Ad2
RV1426/07	JX183011	NPA (i)	F/1.0	pneumonia	2007	Ad3
RV1601/07	JX183020	Sputum (p)	M/30	AGE with sepsis	2007	Ad2
RV1694/07	JX183012	NPA (p)	F/2.6	Acute pharyngotonsillitis	2007	Ad2
RV1816/07	JX183016	NPA (p)	M/0.8	pneumonia	2007	Ad2
RV0018/08	JX183022	NPA (i)	M/0.6	Acute bronchiolitis	2008	Ad5
RV1293/08	JX183024	NPA (p)	M/0.5	Bronchopneumonia	2008	Ad3
RV1907/08	JX183023	ETS (i)	F/0.5	Nosocomial pneumonia	2008	Ad2
RV1987/08	JX183021	NPA (p)	M/0.5	pneumonia	2008	Ad3
RV0087/09*	JX183032	Lung tissue (i)	M/52	Pneumonia	2009	Ad3
RV0224/09	JX183025	NPA (p)	M/1.2	Pneumonia	2009	Ad7
RV0229/09	JX183033	NPA (i)	M/1.0	Bronchopneumonia	2009	Ad3
RV0272/09	JX183026	NPA (i)	M/0.8	Pneumonia	2009	Ad2
RV0322/09	JX183027	NPA (i)	M/0.8	Pneumonia	2009	Ad2
RV0475/09	JX183028	NPA (i)	F/0.4	Nosocomial pneumonia	2009	Ad5
RV0482/09	JX183029	NPA (i)	F/0.5	Pneumonia	2009	Ad1
RV0577/09	JX183030	NPA (i)	F/0.4	Pneumonia	2009	Ad1
RV0725/09	JX183031	NPA (i)	F/0.8	Pneumonia	2009	Ad2
RP0297/10	JX183036	NPA (p)	M/1	Bronchopneumonia	2010	Ad6
RP0320/10	JX183034	ETT (i)	F/1	Severe pneumonia	2010	Ad5
RP0393/10	JX183035	TS (i)	M/5	DHF with pneumonia	2010	Ad3
RP0263/11	JX183054	NPA(p)	M/1	pneumonia	2011	Ad3
RP0301/11*	JX183037	TA (p)	F/22	CAP with respiratory failure	2011	Ad7

Table 1. Contd.

RP0302/11*	JX183038	TA, lung, spleen (p)	F/25	CAP with respiratory failure	2011	Ad7
RP0320/11	JX183058	Stool (i)	M/20	CAP	2011	Ad5
RP0360/11	JX183060	NPA (p)	M/1	Acute bronchiolitis	2011	Ad1
RP0404/11	JX183039	NPA (p)	F/3	Bronchopneumonia	2011	Ad7
RP0423/11	JX183061	NPA (i)	M/1.5	pneumonia	2011	Ad2
RP0460/11	JX183059	NPA (p)	F/0.8	pneumonia	2011	Ad7
RP0485/11	JX183040	TS (i)	M/24	CAP	2011	Ad7
RP0507/11	JX183052	NPA (i)	M/0.8	pneumonia	2011	Ad3
RP0510/11	JX183055	NPA (p)	M/17	Severe pneumonia	2011	Ad7
RP0536/11	JX183062	NPA (p)	M/0.3	pneumonia	2011	Ad5
RP0540/11	JX183056	NPA (p)	F/0.7	Severe pneumonia	2011	Ad7
RP0568/11	JX183041	NPA (i)	M/4.3	pneumonia	2011	Ad2
RP0583/11	JX183042	NPA (p)	F/5	pneumonia	2011	Ad3
RP0592/11	JX183043	NPA (p)	F/0.5	Acute bronchiolitis	2011	Ad7
RP0612/11	JX183044	NPA (p)	M/1.3	pneumonia	2011	Ad3
RP0622/11	JX183045	NPA (i)	F/1.8	Severe pneumonia	2011	Ad3
RP0630/11	JX183046	NPA (i)	F/0.5	pneumonia	2011	Ad3
RP0689/11	JX183051	NPA (i)	M/1	bronchopneumonia	2011	Ad2
RP0695/11	JX183047	ETS (p)	F/0.1	Respiratory distress	2011	Ad6
RP0745/11	JX183048	NPA (p)	M/0.1	pneumonia	2011	Ad3
RP1081/11	JX183049	TS (i)	M/23	CAP	2011	Ad2
RP1082/11	JX183050	TS (i)	M/22	CAP	2011	Ad2
RP1095/11*	JX183053	TS (i)	M/12	Meningoencephalitis	2011	Ad2
RP1098/11	JX183057	TS (i)	M/25	ILI	2011	Ad2

M, Male; F, female; TA, trachea aspirate; NPA, nasopharyngeal aspirate; ETS, endotracheal secretion; TS, throat swab; (i), tissue culture isolate; (p), primary clinical samples; AGE, acute gastroenteritis; DHF, dengue haemorrhagic fever; CAP, community acquired pneumonia; ILI, influenza like illness; \*, denotes fatal case

16 in 2007, and 15 (94%) of the positive PCR samples came from primary clinical specimens. Of the 16 positive samples, 15 were HAdV species C consisting of 9 HAdV-2, 3 HAdV-1 and 1 HAdV-5. HAdV-3 from Species B was identified from the remaining 2 HAdVs positive samples. Four HAdV were isolated in 2008, 2 were from primary clinical specimens and were identified as HAdV-3, and 2 from cell culture were identified as HAdV-5 and HAdV-2.

In 2009, from 9 samples found positive for HAdV, 5 different types were identified namely: HAdV-1, HAdV-2, HAdV-3, HAdV-5 and HAdV-7. In 2010, we detected HAdV-6 in species C for the first time from nasopharyngeal aspirate; together with HAdV-3 and HAdV-5. Most of the positive samples for this study (~35%) were received in 2011 where HAdV-7 was the dominant type followed by HAdV-2, HAdV-3, HAdV-5, HAdV-6 and HAdV-1 (Table 1).

## DISCUSSION

HAdV has been recognised as a cause of ARD, gastrointestinal infection and other simple febrile illness (Horwitz, 2001). Specific HAdV types normally present with specific manifestations and severity (Wold and Horwitz, 2007),

although there are variations in different parts of the world (Baum, 2005). Young children and immunocompromised patients are the most vulnerable to severe complication of HAdV infections (Kojaoghlanian et al., 2003; Walls et al., 2003). In this study, partial hexon gene sequences were used to characterize the HAdV isolates. This gene region contains the hypervariable region and is the most important components for serotype identification of adenoviruses (Takeuchi et al., 1999). The finding showed that 2 species of HAdV; 64% of species C and 36% of species B were found circulating amongst ARD cases in Malaysia from 2003 to 2011. Overrepresentation of HAdV-C at 64% from total adenovirus detected in the past 9 years could suggest a high prevalence of the virus in the community. This finding was consistent with the report from previous study in Malaysia by Abd-Jamil et al. (2010). She found that 70% of the HAdV infection from paediatric patients who sought treatment for respiratory tract infection in UMMC, Malaysia from 1999 to 2005 was species C with HAdV-1 and HAdV-2 were the commonest. These were similar to the findings reported by Garcia et al. (2009) in South America involving 231 characterized adenoviruses collected from influenza like-illness during 2006 to 2008 showed that 161 (76%) adenoviruses belong to species C, 45 (21%) to species B



worldwide distribution and accounted for most of the HAdV associated infections.

Similar situation was also observed in Connecticut (Landry et al., 2009), where an increased incidence of HAdV-3 infections associated with a new variant, HAdV-3a51 that caused mostly mild infections; however, one fatality involving a patient with underlying disease was reported. The same scenario was also observed in Taiwan where HAdV-3 was the commonest HAdV detected among children with RTI from 1999 to 2000 (Hsieh et al., 2009). In our study, HAdV-7 has been found circulating at a low prevalence since 2003 but increased drastically in 2011 with more than 50% of HAdVs isolated were HAdV-7. The frequency of detection increased as a result of the outbreak of HAdV-7 reported in Malaysia in 2011 where there was an increase in both prevalence and disease severity (Apandi et al., 2012). This was similar to the report from Kansas City, where infections with HAdV-7 increased to 25 from 5.6% in the previous two years of surveillance and were associated with severe illness such as acute bronchiolitis and pneumonia (Gray et al., 2007). HAdV-7 was also known to cause outbreaks amongst hospitalised children (Choi et al., 2006; Selvaraju et al., 2011), police/army recruit camps (Apandi et al., 2012), and had the potential for morbidity and mortality. HAdV-7 is a well-known pathogen causing epidemics of severe lower respiratory tract infections in children, with a high mortality rate (Baum, 2005). Global survey has shown approximately one-fifth of all HAdV infections reported to World Health Organization (WHO) were attributed to HAdV-7 (Smith et al., 1983; Erdman et al., 2002). All of our HAdV-7 isolates from 2003, 2009 and 2011 belong to HAdV-7d2 which were very similar to the isolate CQ1198 isolated in China in 2010 from children with severe respiratory infection (Ni et al., 2012 unpublished). The same findings were reported by Selvaraju et al. (2011) where HAdV-7 strains 7d2 were responsible for severe lower respiratory tract infection in children in USA and by Tang et al. (2011), where it was associated with infants' pneumonia in China.

In Malaysia, we reported the first HAdV-7 outbreak in 2011 and it was associated with more severe disease and even fatal cases. Most of HAdV-7 isolated in the study was from patients with respiratory distress, severe pneumonia, bronchiolitis and fatal cases due to respiratory failure. These 2 fatal cases were patients related to the outbreak of HAdV-7 in Police Training Centre as reported by Apandi et al. (2012). HAdV-7 has been documented in outbreaks either among infants, older children or adults with serious outcomes (Wadell et al., 1980). The HAdV-7d2 strain was first reported in 1998 by Azar et al. (1998) and since then became the prevalent dominant strain of HAdV-7. In China, HAdV-7d was dominant during 1980 to 1994 and was a representative genome type in Asian until 1998 (Zhang et al., 1986) and associated with higher fatality rate than HAdV-3 (Li et al., 1996) and Erdman et al. (2002) reported 2

emergent genome types of HAdV-7 and both were associated with epidemic, severe illness and death. Other serotypes from species B, HAdV-11 and HAdV-14 which previously have been associated with acute respiratory disease with fatal outcome (Zhu et al., 2009; Ou et al., 2008), involved in outbreak associated pneumonia (Esposito et al., 2010) and fatal pneumonia (Hong et al., 2001; Tate et al., 2009) were not found in the study.

## Conclusion

This study showed that only 2 species of adenovirus were found circulating among ARD cases in Malaysia in the 9 years period from 2003 to 2011. Majority was HAdV species C at 64% and the remaining 36% (26/73) was HAdV species B. The predominant type was HAdV type 2, followed by HAdV-3, HAdV-7, HAdV-1, HAdV-5 and HAdV-6. HAdV-7 was found to be associated with severe clinical presentations.

## ACKNOWLEDGEMENTS

The authors would like to thank the Director General of Health and the Director of the Institute for Medical Research for permission to publish this paper. We would like to acknowledge the staff of the Virology unit in IMR for their technical contributions and laboratory staff from the government hospitals in Malaysia for sending the specimens to IMR. This research project was funded under JPP 11-024.

## REFERENCES

- Abd-Jamil J, Teoh BT, Hassan EH, Nuruliza R, Szalay AB (2010). Molecular identification of adenovirus causing respiratory tract infection in paediatric patients at the University of Malaya Medical Center. *BMC Paed.* 10:46.
- Apandi Y, Tengku RTAR, Thayan R, Khairul AO, Norhasnida AH, Norfaezah A, Zainah S (2012). Human adenovirus type 7 outbreak in Police Training Center, Malaysia, 2011. *Emerg. Infect. Dis.* 18(5): 852-854.
- Azar R, Varsano M, Mileguir F, Mendelson E (1998). Molecular epidemiology of adenovirus type 7 in Israel: Identification of two new genome types, Ad7k and Ad7d2. *J. Med. Virol.* 54:291-299.
- Baum SG (2005). Adenovirus. In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett's principles and practice of infectious diseases.* 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone. pp. 1835-41.
- Berciaud S, Rayne F, Kassab S, Jubert C, Faure-Della CM, Salin F, Wodrich H, Lafon ME (2012). Typadeno Study Members. Adenovirus infections in Bordeaux University Hospital 2008-2010: *Clin. virol. features. J. Clin. Virol.* 54: 302-307.
- Carballal G, Videla C, Misirlian A, Requeijo PV, Aguilar MC (2002). Adenovirus type 7 associated with severe and fatal acute lower respiratory infections in Argentine children. *BMC Pediatr.* 2: pg. 6.
- Casas I, Avellon A, Mosquera M, Jabado O, Echevarria JE, Campos RH, Rewers M, Perez-Breña P, Lipkin WI, Palacios GI (2005). Molecular identification of adenoviruses in clinical samples by analyzing a partial hexon genomic region. *J. Clin. Microbiol. Dec;* 43(12):6176-82.
- CDC (2007). Acute respiratory disease associated with adenovirus serotype 14-Four states, 2006-200. *Morb. Mortal weekly Rep.*

- 56:1181-4
- Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, Lee JH, Song EK, Kim SH. (2006). Ten year analysis of adenovirus type 7 molecular epidemiology in Korea, 1994-2004: Implication of fiber diversity. *J. Clin. Virol.* 35(4):388-393.
- Crawford IL, Schnurr DP (1996). Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. *J. Virol.* 70: 1836-1844.
- Dudding BA, Wagner SC, Zellar SC, Gmelith JT, French GR, Top FH (1972). Fatal pneumonia associated with adenovirus type 7 in three military trainees. *N Engl. J. Med.* 286:1289-1292.
- Erdman DD, Xu W, Gerber SI, Gray GC, Schnurr D, Kajon AE, Anderson LJ (2002). Molecular epidemiology of adenovirus type 7 in the United States, 1966-2000. *Emerg. Infect. Dis.* 8:269-277.
- Esposito DH, Gardner TJ, Schneider E, Stockman LJ, Tate JE, Panozzo CA, Robbins CL, Jenkinson SA, Thomas L, Watson CM, Curns AT, Erdman DD, Lu X, Cromeans T, Westcott M, Humphries C, Ballantyne J, Fischer GE, McLaughlin JB, Armstrong G, Anderson LJ (2010). Outbreak of pneumonia associated with emergent human adenovirus serotype 14--Southeast Alaska, 2008. *J. Infect. Dis.* Jul 15; 202(2):214-22. doi: 10.1086/653498.
- Finn A, Andy E, Talbot GH (1988). An epidemic of adenovirus 7a infection in a neonatal nursery: course, morbidity and management. *Infect. Control Hosp. Epidemiol.* 9:394-404.
- Genzenmueller T, Buchholz S, Harste G, Dammann E, Trenschele R, Heim A (2011). High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load. *J. Clin. Virol.* 2011;52:55-9.
- Garcia J, Sovero M, Laguna-Torres VA, Gomez J, Chicaiza W, Barrantes M, Sanchez F, Jimenez M, Comach G, de Rivera IL, Agudo R, Arango AE, Barboza A, Aguayo N, Kochel TJ (2009). Molecular characterization of adenovirus circulating in Central and South America during the 2006-2008 period. *Influenza Other Resp. Viruses.* 3(6):327-30.
- Gray GC, McCarthy T, Lebeck MG, Schnurr DP, Russell KL, Adriana KAE, Landry LM, Leland DS, Storch GA, Ginocchio CC, Robinson CC, Demmler GJ, Saubolle MA, Kehl SC, Selvarangan R, Miller MB, Chappell JD, Zerr DM, Kiska DL, Halstead DC, Capuano AW, Setterquist SF, Chorazy ML, Dawson JD, Erdman DD (2007). Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. *Clin. Infect. Dis.* 45:1120-31.
- Gu L, Liu Z, Li X, Qu J, Guan W, Liu Y, Song S, Yu X, Cao B (2012). Severe community-acquired pneumonia caused by adenovirus type 11 in immunocompetent adults in Beijing. *J. Clin. Virol.* 54(4): 295-301.
- Hilleman MR, Werner JH (1954). Recovery of new agent from patients with acute respiratory illness. *Proc. Soc. Exp. Biol. Med.* 85:183-188.
- Hong JY, Lee HJ, Piedra PA, Choi EH, Park KH, Koh YY, Kim WS (2001). Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. *Clin. Infect. Dis.* 32: 1423-1429.
- Horwitz MS (2001). Adenoviruses. In *Fields Virology* 4th edition. Edited by: Fields BN, Knipe DM, Howley PM, Griffin DE. Philadelphia: Lippincott Williams & Wilkins; 2001:2301-2326.
- Hsieh WY, Chiu NC, Chi H, Huang FY, Hung CC (2009). Respiratory adenoviral infections in Taiwanese children: a hospital-based study. *J. Microbiol. Immunol. Infect.* 42(5): 371-377.
- Institute of Health and Community Medicine (2003). Standard operating procedure for hand, foot and mouth disease outbreak in UNIMAS Sarawak.
- Kajon AE, Dickson LM, Metzgar D, Hong HS, Lee V, Tan BH (2010). Outbreak of febrile respiratory illness associated with adenovirus 11a infection in a Singapore Military training Camp. *J. Clin. Microbiol.* 48(4): 438-1441.
- Kajon AE, Moseley JM, Metzgar D, Huong HS, Wadleigh A, Ryan MA, Russell KL (2007). Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997-2003). *J. Infect. Dis.* 196:67-75.
- Kandel R, Srinivasan A, D'Agata EM, Lu X, Erdman D, Jhung M (2010). Outbreak of adenovirus type 4 infection in a long term care facility for the elderly. *Infect. Cont. Hosp. Epidemiol.* 31(7): 755-757.
- Kojaoghlanian T, Flomenberg P, Horwitz MS (2003). The impact of adenovirus infection on the immunocompromised host. *Rev. Med. Virol.* 2003, 13:155-171.
- Landry ML, Lebeck MG, Capuano AW, McCarthy T, Gray GC (2009). Adenovirus type 3 outbreak in Connecticut associated with a novel variant. *J. Med. Virol.* 81(8): 1380-1384.
- Lee J, Choi EH, Lee HJ (2010). Comprehensive serotyping and epidemiology of human adenovirus isolated from the respiratory tract of Korean children over 17 consecutive years (1991-2007). *J. Med. Virol.* 82(4): 624-631.
- Li QG, Zheng QJ, Liu YH, Wadell G (1996). Molecular epidemiology of adenovirus type 3 and 7 isolated from children with pneumonia in Beijing. *J. Med. Virol.* 49:170-177.
- Mandell GL, Bennett JE, Dolin R (2009). *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*, 7th ed Churchill Livingstone/Elsevier, Philadelphia, PA.
- Martin MA, Knipe DM, Fields BN, Howley PM, Peter M, Griffin D, Lamb R (2007). *Fields' virology*. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins. Pp. 2395.
- Metzgar D, Osuna M, Yingst S, Rakha M, Earhart K, Elyan D, Esmat H, Saad MD, Kajon A, Wu J, Gray GC, Ryan MAK, Russell KL (2005). PCR analysis of Egyptian respiratory adenovirus isolates, including identification of species, serotypes, and coinfections. *J. Clin. Microbiol.* 43: 5743-5752.
- Ou ZY, Zeng QY, Wang FH, Xia HM, Lu JP, Xia JQ, Gong ST, Deng L, Zhang JT, Zhou R (2008). Retrospective study of adenovirus in autopsy pulmonary tissue of pediatric fatal pneumonia in South China. *BMC Infect. Dis.* 8:122.
- Pereira HG (1972). Persistent infection by adenoviruses. *J. Clin. Pathol. Suppl.* 6:39-42.
- Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. *Proc. Soc. Exp. Biol. Med.* 84: 570-573.
- Rubin BA (1993). Clinical picture and epidemiology of adenovirus infections. *Acta Microbiol Hung* 1993, 40:303-323.
- Schmitz H, Wigand R, Heinrich W (1983). Worldwide epidemiology of human adenovirus infections. *Am. J. Epidemiol.* 117: 455-466.
- Selvaraju SB, Kovac M, Dickson LM, Kajon AE, Selvarangan R (2011). Molecular epidemiology and clinical presentation of human adenovirus infections in Kansas City Children. *J. Clin. Virol.* Doi: 10.1016/j.jcv.2011.02/014.
- Seto D, Chodosh J, Brister JR, Jones MS (2011). Using the whole genome sequence to characterize and name human adenoviruses. *J. Virol.* 85:5701-5702.
- Straube RC, Thompson MA, Van Dyke RB, Wadell G, Connor JD, Wingaed D, Spector A (1983). Adenovirus type 7b in children's hospital. *J. Infect. Dis.* 147:814-819.
- Takeuchi K, Itoh N, Uchio E, Aoki K, Ohno S (1999). Serotyping of adenoviruses on conjunctival scrapings by PCR and sequence analysis. *J. Clin. Microbiol.* 37: 1839-1845.
- Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. *Mol. Biol. Evol.* 24:1596-1599.
- Tang L, Wang L, Tan X, Xu W (2011). Adenovirus serotype 7 associated with a severe lower respiratory tract disease outbreak in infants in Shaanxi Province, China. *Virol. J.* 8:23.
- Tate JE, Bunning ML, Lott L, Lu X, Su J, Metzgar D, Brosch L, Panozzo CA, Marconi VC, Faix DJ, Prill M, Johnson B, Erdman DD, Fonseca V, Anderson LJ, Widdowson MA (2009). Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. *J. Infect. Dis.* 199 (10): 1419-26.
- Trei JS, Johns NM, Garner JL, Noel LB, Ortman BV, Ensz KL, Johns MC, Bunning ML, Gaydos JC (2010). Spread of adenovirus to geographically dispersed military installations, May-October 2007. *EID. www.cdc.gov/eid.* 16 (5);769-775.
- Tsolia MN, Psarras S, Bossios A, Audi H, Paldanius M, Gourgiotis D, Kallergi K, Kafetzis DA, Constantopoulos A, Papadopoulos NG (2004). Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. *Clin. Infect. Dis.* 39(5): 681-686.
- Wadell G, Versanyi TM, Lord A, Sutton RN (1980). Epidemic outbreaks

- of adenovirus 7 with special reference to the pathogenicity of adenovirus genome type 7b. *Am. J. Epidemiol.* 112:619-628.
- Walls T, Shankar AG, Shingadia D (2003). Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. *Lancet Infect. Dis.* 3:79-86.
- Walsh MP, Seto J, Liu EB, Dehghan S, Hudson NR, Lukashov AN, Ivanova O, Chodosh J, Dyer DW, Jones MS, Seto D (2011). Computational analysis of two species C human adenoviruses provides evidence of a novel virus. *J. Clin. Microbiol.* 49(10): 3482-90. doi: 10.1128/JCM.00156-11. Epub 2011 Aug 17.
- Wold WS, Horwitz MS (2007). Adenoviruses. In: Knipe DM, Howley PM, editors. *Fields virology*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, Inc. 2395-436.
- Yeung R, Eshaghi AR, Lombos E, Blair J, Mazzulli T, Burton L, Drews SJ (2009). Characterization of culture-positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada. *Virology* 400(1): 1-3.
- Zhang ZJ, Wang ZL, Cao YP, Zhu ZH, Liu YL, Lin LM, Gao X (1986). Acute respiratory infections in childhood in Beijing: An aetiological study of pneumonia and bronchiolitis. *Clin. Med. J.* 99:695-702.
- Zhu Z, Zhang Y, Xu S, Yu P, Tian X, Wang L, Liu Z, Tang L, Mao N, Ji Y, Li C, Yang Z, Wang S, Wang J, Li D, Xu W (2009). Outbreak of acute respiratory disease in China caused by B2 species of adenovirus type 11. *J. Clin. Microbiol.* 47(3): 697-703.